• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vaxart Inc

    2/9/23 11:35:17 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VXRT alert in real time by email
    SC 13G 1 tv02164-vaxartinc.htm SCHEDULE 13G vaxartinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Vaxart Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  92243A200

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  92243A200

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    98,997

    7.  SOLE DISPOSITIVE POWER

    6,875,045

    8.  SHARED DISPOSITIVE POWER

    144,462

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,019,507

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.35%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Vaxart Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    170 Harbor Way, Suite 300
    South San Francisco, CA 94080

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    92243A200

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $VXRT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VXRT

    DatePrice TargetRatingAnalyst
    8/15/2024$4.00Outperform
    Oppenheimer
    12/29/2021$13.00 → $12.00Buy
    Jefferies
    11/2/2021$15.00Overweight
    Cantor Fitzgerald
    6/30/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/29/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $VXRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Finney Kevin was granted 6,103 shares, increasing direct ownership by 19% to 38,103 units (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      6/16/25 9:06:17 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Watson W. Mark was granted 16,000 shares, increasing direct ownership by 20% to 94,125 units (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      6/16/25 9:05:24 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Heron Elaine J was granted 16,000 shares, increasing direct ownership by 39% to 56,566 units (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      6/16/25 9:04:33 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    SEC Filings

    See more
    • Vaxart Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vaxart, Inc. (0000072444) (Filer)

      7/8/25 5:13:12 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Vaxart, Inc. (0000072444) (Filer)

      7/2/25 8:00:28 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vaxart, Inc. (0000072444) (Filer)

      6/17/25 4:20:52 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Vaxart with a new price target

      Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00

      8/15/24 7:45:56 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies resumed coverage on Vaxart with a new price target

      Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      12/29/21 7:23:57 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Vaxart with a new price target

      Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00

      11/2/21 7:42:45 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, Chief Exec Officer Lo Steven bought $49,000 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/19/25 6:49:39 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Watson W. Mark bought $13,578 worth of shares (20,000 units at $0.68), increasing direct ownership by 34% to 78,125 units (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      6/20/24 6:10:10 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxart Announces Trading on OTCQX Best Market

      SOUTH SAN FRANCISCO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its common stock has been approved to trade on the OTCQX® Best Market. The Company's shares will commence trading at the open of the market on July 8, 2025, under its existing ticker symbol "VXRT." Shareholders will not need to take any action. The OTCQX Market, being the highest tier of OTC Markets Group, enables Vaxart to provide the greatest transparency, visibility, and accessibility to investors available in the OTC Mar

      7/8/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

      NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market. Vaxart, Inc. previously traded on NASDAQ. Vaxart, Inc. begins trading today on OTCQX under the symbol "VXRT." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to he

      7/8/25 7:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vicarious Surgical Announces Election of New Directors

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting. "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and th

      6/30/25 6:45:00 AM ET
      $GSAT
      $IRIX
      $JNJ
      $MITK
      Telecommunications Equipment
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VXRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxart Appoints Jeroen Grasman as Chief Financial Officer

      - Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025. "We are delighted to welcome Jeroen to the Vaxart team," said Steven Lo, Chief Executive Officer of Vaxart. "His extensive financial expertise and proven track record in the biotech sector, includ

      5/13/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

      Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced the appointment of Kevin Finney to the Company's Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. "Kevin adds a wealth of healthcare industry experience spanning executive leadership, governance, operations, and corporate deve

      1/28/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

      Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Ch

      3/6/24 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Financials

    Live finance-specific insights

    See more
    • Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

      - Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection - - Vaccine candidates were safe and well-tolerated across all dose groups with no vaccine-related serious adverse events reported - - Conference call today at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported positive t

      6/11/25 7:30:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

      SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International:

      6/10/25 4:47:38 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

      Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025 New avian influenza vaccine candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals Jeroen Grasman appointed as Chief Financial Officer effective May 19, 2025 Cash, cash equivalents and investments of $41.9 million as of March 31, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 13, 2025 (

      5/13/25 4:05:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

      SC 13G/A - Vaxart, Inc. (0000072444) (Subject)

      2/13/24 5:16:04 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Vaxart Inc

      SC 13G - Vaxart, Inc. (0000072444) (Subject)

      1/19/24 4:30:58 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Vaxart Inc

      SC 13G - Vaxart, Inc. (0000072444) (Subject)

      2/9/23 11:35:17 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care